Bubendorf, Switzerland, Thursday, December 12, 2019 – A new method for the modification of PEEK surfaces was established that significantly increases hydrophilicity of the material surface. The novel method is a scalable and convenient process and can be tailored to the desired physical properties of the PEEK surface. In preliminary cell culture experiments the modified PEEK surfaces have shown positive results. Currently CIS Pharma is evaluating pre-clinical and clinical strategy moving the project into the next phase.
About CIS Pharma Biomaterials
CIS Pharma has developed a platform of proprietary polymers, including a toolki, to create biomaterials specific to their application and site of use. The platform polymers are applicable in the fields of nanotechnology, diagnostics and biomedicine. Tissue regeneration, lab-on-a-chip assays and scaffolds releasing active agents are targeted applications. Novel polymer structures offer contact points for conjugation and delivery of therapeutics. The structures are adapted to fit the chemical and physical properties of the therapeutics and the site of delivery. Conjugated active compounds comprise small molecules as well as large protein-based drugs. Specific linker chemistry is applied to control the release kinetics of conjugated therapeutics.
Both the platform monomers as well as polymers show excellent biocompatibility, superior to commonly used building blocks in the implant industry. The safety of our building blocks has been demonstrated in cytotoxicity and genetoxicity models.
About CIS Pharma AG
CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of therapeutics that are the standard of care, thereby improving patient’s experience and treatment outcome. Medical need, patient centricity and digital technology are key to our research and development programs. CIS Pharma is located in the region of Basel, Switzerland, one of the most successful life sciences locations in the world. For more information about the company, visit our website www.cis-pharma.com.